STING1 and cancer: The proinflammatory cytokines IFNβ1 and CXCL10 were also elicited by low-dose TLC388 (0.5-1.0 μM, Fig. 2B and C), indicating that TLC388 has a superior ability to activate STING-mediated IFN-I production, thereby enhancing cancer immunogenicity, especially in cells with low immunogenicity.